| +0.49 / +3.23%|
The 15 analysts offering 12-month price forecasts for Sarepta Therapeutics Inc have a median target of 22.00, with a high estimate of 54.00 and a low estimate of 13.00. The median estimate represents a +40.31% increase from the last price of 15.68.
The current consensus among 17 polled investment analysts is to Hold stock in Sarepta Therapeutics Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.